Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Biomark DiagnosticsBMKDF 24 EV-to-EBIT is -40.66 as of Aug. 03, 2026. GuruFocus rates BMKDF with a GF Score™ of 24/100. The stock has 4 warning signs investors should review. Among 105 Medical Diagnostics & Research companies, Biomark Diagnostics ranks worse than 952380% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Biomark Diagnostics's Enterprise Value for the quarter that ended in Mar. 2026 was $45.69 Mil.
Biomark Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics EV-to-EBIT Related Terms
Biomark Diagnostics EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Biomark Diagnostics's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Biomark Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomark Diagnostics EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomark Diagnostics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Biomark Diagnostics's EV-to-EBIT falls into.
Biomark Diagnostics's current Enterprise Value is $41.80 Mil.
Biomark Diagnostics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.03 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomark Diagnostics (BMKDF) has a EV-to-EBIT of -40.66 as of Aug. 03, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biomark Diagnostics and its competitors. According to the industry distribution chart, Biomark Diagnostics ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry.
Is Biomark Diagnostics' EV-to-EBIT too high?
Biomark Diagnostics' current EV-to-EBIT is -40.66. Based on the distribution chart, Biomark Diagnostics ranks #999999 out of 105 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomark Diagnostics has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Biomark Diagnostics' EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomark Diagnostics ranks #999999 out of 105 companies for EV-to-EBIT. This places Biomark Diagnostics in the lower half of its industry. The industry median EV-to-EBIT is 23.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 23.07, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Biomark Diagnostics and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 23.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomark Diagnostics's current EV-to-EBIT is -40.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomark Diagnostics stock overvalued right now?
Biomark Diagnostics (BMKDF) has a current EV-to-EBIT of -40.66. The current EV-to-EBIT is -40.66. Biomark Diagnostics' overall GF Score™ is 24/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Biomark Diagnostics (BMKDF), the current EV-to-EBIT is -40.66 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early cancer treatment. Its research and development are focused on the role that metabolomics plays in early cancer detection. The company's objective is to commercialize its inventive technology. and strive to increase the predictive accuracy in early-stage cancer detection.
24GF Score
Get the complete analysis for BMKDF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMKDF has been successfully added to your 
